Fifty percent of patients who had survived beyond 6 months showed an increase in IFNγ spots during treatment compared with baseline (Fig. 5C and E), meaning that treatment with MVX-ONCO-1 can trigger a tumor-specific immune response from PBMCs in this patient population. The gene discussed is IFNG; the disease is neoplasm.